VivoSeq
Cardiovascular

Cardiac Repolarization

2

Pipeline Programs↗

1

Active Trials↗

27

Companies Involved↗

Cardiac Repolarization is an early-stage landscape with 2 programs across 27 companies. The most active players are Sanofi, Bayer, Eli Lilly.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

11/100

Mech. Concentration

100/100

Completion Rate

97/100

Attrition Rate

3/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

1 program

Phase 1Bayer logo

Bayer

1 program

Phase 1Eli Lilly logo

Eli Lilly

1 program

Phase 1Johnson & Johnson logo

Johnson & Johnson

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalAstellas logo

Astellas

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 12

Balinatunfib

Sanofi

Moxifloxacin

Bayer

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

62

clinical trials

Completed57 · 92%
Terminated2 · 3%
Unknown status2 · 3%
Recruiting1 · 2%

Clinical Trials

Trial Activity

62 trials

A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT07422298·32 enrolled
Effects of HSK3486 on Cardiac Repolarization in Health Subjects (TQT)
Completed·HHaisco-USA Pharmaceuticals, Inc.·Phase 1·NCT06795204·48 enrolled
Study Evaluating the Effects of MOA-728 on Cardiac Repolarization in Healthy Subjects
Completed·BBausch Health Americas, Inc.·Phase 1·NCT00434395
Nebulized Bronchodilators and Cardiac Repolarization
Completed·MMedical University of Gdansk·N/A·NCT01714401·50 enrolled
A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT03606057·188 enrolled
Selections of Subjects With Important Changes in Their Cardiac Repolarization Parameters for the Procurement of Skin and Blood Samples
Completed·EEctycell SASU·Phase 1·NCT01338441·130 enrolled
Droperidol and Cardiac Repolarization
Completed·MMedical University of Gdansk·Phase 4·NCT01819857·75 enrolled
A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT02658825·66 enrolled
A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy Participants
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT06589726·40 enrolled
T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers
Completed·CCorcept Therapeutics·Phase 1·NCT04795479·36 enrolled
A Study of the Effect of ASP1941 on Cardiac Repolarization in Healthy Subjects
Completed·Astellas logoAstellas·Phase 1·NCT01232413·88 enrolled
A Study to Evaluate the Effect of Repeat Oral Doses of YM443 on Cardiac Repolarization in Healthy Adults
Completed·Astellas logoAstellas·Phase 1·NCT00850746·80 enrolled
Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Chinese Healthy Participants
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT02816853·44 enrolled
Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization
Completed·BBial - Portela C S.A.·Phase 1·NCT02283788·67 enrolled
A Study With an Open-Label Active Control to Evaluate the Potential of Nestorone® to Delay Cardiac Repolarization in Healthy Female Volunteers
Completed·PPopulation Council·Phase 1·NCT02236026·44 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)